|
시장보고서
상품코드
2075818
실데나필 의약품 시장 : 의약품 유형별, 적응증별, 유통 채널별, 제형별, 지역별Sildenafil Drug Market, By Drug Type, By Indication, By Distribution Channel, By Dosage Form, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
실데나필 의약품 시장은 2026년에 35억 3,000만 달러 규모에 이를 것으로 추정되며, 2033년까지 56억 3,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 6.9%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 35억 3,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 6.90% | 시장 규모 예측(2033년) : | 56억 3,000만 달러 |
일반적으로 '작은 파란 알약'으로 알려진 실데나필은 주로 발기부전(ED) 치료에 널리 사용되는 의약품입니다. 이는 포스포디에스테라제 5형(PDE5) 억제제라고 불리는 약물군에 속하며, '비아그라'라는 상품명으로 판매되고 있습니다. 실데나필은 음경 혈관에 있는 평활근을 이완시켜 작용하며, 이를 통해 혈류를 증가시켜 궁극적으로 발기를 촉진합니다.
1990년대 후반에 도입된 이래, 실데나필은 발기부전 치료 분야에 혁명을 일으키며 전 세계 수백만 명의 남성에게 희망을 안겨주었습니다. 발기 달성이나 유지에 어려움을 겪는 사람들에게 실데나필은 믿음직한 의약품이 되어, 많은 사람들의 삶을 완전히 바꿔놓는 효과적인 해결책을 제공합니다.
시장 역학 :
실데나필 시장은 예측 기간 동안 상당한 성장이 예상됩니다. 이러한 성장의 주요 요인으로는 세계 발기부전 유병률 증가, 고령화의 진행, 그리고 성 건강에 대한 인식 제고를 들 수 있습니다.
그러나 시장에는 과제도 존재합니다. 큰 제약 요인은 시중에 유통되고 있는 실데나필 위조품이며, 이러한 제품들은 소비자에게 심각한 건강 위험을 초래할 가능성이 있습니다. 규제 당국과 제약사들은 위조 의약품 단속에 전력을 다하고 있습니다.
이러한 과제가 있음에도 불구하고, 실데나필 시장에는 몇 가지 기회가 존재합니다. 구강 내 용해정이나 츄어블정과 같은 혁신적인 제형의 개발은 환자에게 편의성과 투여의 용이성을 제공합니다. 또한, 실데나필 제네릭 의약품의 등장으로 약값이 저렴해지고 구하기 쉬워짐에 따라 시장 성장이 촉진될 것으로 예측됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 시장 세분화 분야에서 잠재적인 수익 기회를 모색하고, 이 시장에 대한 매력적인 투자 제안을 제시하고 있습니다.
- 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 보고서에서는 세계 실데나필 의약품 시장의 주요 기업 프로파일을 소개하며, 각 기업의 배경, 제품 포트폴리오, 주요 실적, 재무 실적 및 전략에 초점을 맞추었습니다.
- 본 조사에는 Pfizer, Teva Pharmaceuticals, Aurobindo Pharma, Alembic Pharmaceuticals, Torrent Pharmaceuticals, Lupin, Dr Reddy's Laboratories, Zydus Cadila, Amneal Pharmaceuticals, Hetero, Apotex, Mylan, Ajanta Pharma, Sun Pharmaceutical, Cipla, Novartis, Eli Lily, Sanofi, Bayer 및 GlaxoSmithKline 등의 주요 기업이 포함되어 있습니다.
- 본 보고서가 제공하는 인사이트는 마케팅 담당자 및 경영진이 제품 출시, 업그레이드, 시장 확대 및 마케팅 전략과 관련하여 충분한 정보를 바탕으로 의사결정을 내릴 수 있도록 도울 것입니다.
- 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자들이 본 보고서의 조사 결과를 통해 혜택을 얻을 수 있습니다.
- 이해관계자들은 실데나필 의약품 시장 분석에 사용된 전략 매트릭스를 활용하여 의사결정 과정을 원활하게 진행할 수 있습니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 실데나필 의약품 시장 : 약제 유형별(2021-2033년)
제5장 실데나필 의약품 시장 : 적응증별(2021-2033년)
제6장 실데나필 의약품 시장 : 유통 채널별(2021-2033년)
제7장 실데나필 의약품 시장 : 제형별(2021-2033년)
제8장 실데나필 의약품 시장 : 지역별(2021-2033년)
제9장 경쟁 구도
제10장 섹션
AJY 26.07.09Sildenafil Drug Market is estimated to be valued at USD 3.53 Bn in 2026 and is expected to reach USD 5.63 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.53 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.90% | 2033 Value Projection: | USD 5.63 Bn |
Sildenafil which is commonly known as the little blue pill, is a widely used drug primarily used to treat erectile dysfunction (ED). It belongs to the class of medications called phosphodiesterase type 5 (PDE5) inhibitors and is marketed under the brand name Viagra. Sildenafil works by relaxing the smooth muscles of the blood vessels in the penis, thereby allowing for increased blood flow and ultimately facilitating an erection.
Since its introduction in the late 1990s, sildenafil has revolutionized the field of ED treatment, providing relief to millions of men worldwide. It has become the go-to medication for individuals experiencing difficulties in achieving and maintaining an erection, thereby offering an effective solution that has transformed the lives of many.
Market Dynamics:
The sildenafil drug market is expected to witness significant growth in the forecast period. The key drivers for this growth include the increasing prevalence of erectile dysfunction worldwide, the growing aging population, and the rising awareness regarding sexual health.
However, the market has also challenges. The significant restraint is the presence of counterfeit sildenafil products in the market, which can pose serious health risks to consumers. Regulatory bodies and pharmaceutical companies are making efforts to crack down on counterfeit drugs.
Despite these challenges, the sildenafil market presents several opportunities. The development of innovative dosage forms, such as orally disintegrating tablets and chewable tablets, offers convenience and ease of administration for patients. The emergence of generic versions of sildenafil is expected to drive the market growth by making the drug more affordable and accessible.
Key Features of the Study:
- The study explores potential revenue opportunities across different market segments and presents attractive investment propositions for this market
- It offers key insights into market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- The report profiles key players in the global sildenafil drug market, highlighting their company background, product portfolio, key accomplishments, financial performance, and strategies
- The study includes key companies such as Pfizer, Teva Pharmaceuticals, Aurobindo Pharma, Alembic Pharmaceuticals, Torrent Pharmaceuticals, Lupin, Dr Reddy's Laboratories, Zydus Cadila, Amneal Pharmaceuticals, Hetero, Apotex, Mylan, Ajanta Pharma, Sun Pharmaceutical, Cipla, Novartis, Eli Lily, Sanofi, Bayer, and GlaxoSmithKline.
- The insights provided by this report would enable marketers and management authorities to make informed decisions regarding product launches, upgrades, market expansion, and marketing tactics
- Various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts, would benefit from the findings of this report
- Stakeholders can leverage the strategy matrices used in analyzing the sildenafil drug market to facilitate decision-making processes
Detailed Segmentation:
- Sildenafil Drug Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
- Branded Drugs
- Generic Drugs
- Over The Counter Drugs
- Sildenafil Drug Market, By Indication (Revenue, USD Bn, 2021 - 2033)
- Erectile Dysfunction
- Pulmonary Arterial Hypertension
- Benign Prostatic Hyperplasia
- Others (Premature Ejaculation, Altitude Sickness)
- Sildenafil Drug Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Clinics, Mail Order Pharmacies)
- Sildenafil Drug Market, By Dosage Form (Revenue, USD Bn, 2021 - 2033)
- Tablets
- Oral Jellies
- Injections
- Others (Suspensions, Capsules)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in Sildenafil Drug Market:
- Pfizer
- Teva Pharmaceuticals
- Aurobindo Pharma
- Alembic Pharmaceuticals
- Torrent Pharmaceuticals
- Lupin
- Reddy's Laboratories
- Zydus Cadila
- Amneal Pharmaceuticals
- Hetero
- Apotex
- Mylan
- Ajanta Pharma
- Sun Pharmaceutical
- Cipla
- Novartis
- Eli Lily
- Sanofi
- Bayer
- GlaxoSmithKline
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Dosage Form
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Increasing prevalence of erectile dysfunction
- Restraints
- Adverse effects and safety concerns
- Opportunities
- Development of novel drug delivery system
- Drivers
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, ad Collaborations
4. Sildenafil Drug Market, By Drug Type, 2021-2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Generic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Over The Counter Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Sildenafil Drug Market, By Indication, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Erectile Dysfunction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Pulmonary Arterial Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Benign Prostatic Hyperplasia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Premature Ejaculation, Altitude Sickness)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Sildenafil Drug Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Clinics, Mail Order Pharmacies)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
7. Sildenafil Drug Market, By Dosage Form, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Oral Jellies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Suspensions, Capsules)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
8. Sildenafil Drug Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 -2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(US$ Bn)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Company Profile
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Torrent Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amneal Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hetero
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Apotex
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ajanta Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eli Lily
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bayer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Analyst Views
10. Section
- References
- Research Methodology
- About us
